Funding for this research was provided by:
National Health and Medical Research Council
The Merchant Foundation
Received: 25 June 2018
Accepted: 11 September 2018
First Online: 8 October 2018
Ethics approval and consent to participate
: The study protocol was approved by the Griffith University Human Research Ethics Committee (GLY/01/14/HREC). The study was conducted in accordance with the principles of the Declaration of Helsinki and the standards of Good Clinical Practice as defined by the International Conference on Harmonisation. Written informed consent was obtained from all participants prior to commencement of the study. The use of human blood products for culture of <i>P. falciparum</i> and <i>P. knowlesi</i> was approved by the Griffith University Human Research Ethics Committee (BDD/02/14/HREC). As part of standard Australian Red Cross Blood Service practice, donors consent each time they donate blood or blood products for the use of their donation for research purposes.
: Consent to publish data from the study was obtained from all participants prior to commencement of the study.
: DS, XL, IED, IR, JP, NW, SD, MH and MG declare competing interests. At the time of this study, they were employees of Griffith University, which co-owns a patent family “Blood-Stage Malaria Vaccine”. This patent family is related to the work described in this manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.